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Abstract
Purpose Tacrolimus is a potent immunomodulator that
is effective in the treatment of inflammatory bowel dis-
ease (IBD). However, potential toxicity and systemic
effects with oral intake limit its use. Local tacrolimus
treatment is effective in a subgroup of proctitis patients.
This study aimed to evaluate whether colonic mucosal
immune cells are susceptible to locally applied tacrolimus
in vitro. Our in vivo studies aimed at evaluating whether
local tacrolimus treatment in mice would bring about
local immune suppression and to compare colonic and
systemic tacrolimus levels after locally and systemically
applied tacrolimus.
Results In vitro tacrolimus inhibited the activation of
multiple cell types present in colonic tissue; lamina propria
T cells, NKT cells, and both classical- and non- classical
antigen presenting cells. However, the cytokine production
of epithelial cells was not inhibited by tacrolimus at these
concentrations. After rectal administration in mice, ta-
crolimus blood levels were comparable to those obtained
by oral intake. However, rectally treated mice exhibited a
14-fold higher concentration of tacrolimus within their
colonic tissue than orally treated mice. Moreover, rectally
applied tacrolimus resulted in a local but not a systemic
immune suppression in mice.
Conclusions Tacrolimus inhibits activation of several
pivotal immune cells of the intestinal mucosa. Murine
studies indicate that colonic application of tacrolimus
induces local rather than systemic immune suppression.
Keywords Colonic mucosa  Tacrolimus 
Local immune suppression 
Inflammatory bowel disease (IBD)
Introduction
Calcineurin inhibitors, such as tacrolimus and cyclospor-
ine, are a subset of immunomodulators that potently inhibit
lymphocyte proliferation and activation [1]. They are best
known for their immunosuppressive capacities in preven-
tion of allograft rejection. In addition, systemic treatment
with calcineurin inhibitors has been shown to be effective
in the treatment of IBD. However, general systemic
immune suppression, potential side-effects (insulin resis-
tance, hypertension, neurological disorders) and potential
toxicity (hepatotoxitcity and nephrotoxicity) limit the use
of calcineurin inhibitors.
Local treatment of colitis patients by means of enemas
or suppositories of various drugs is associated with local
efficacy and less systemic side-effects. As such, prednisone
and 5-ASA enemas and suppositories are widely prescribed
for IBD patients with distal colitis or proctitis. Unfortu-
nately, there is a subset of patients unresponsive to these
local treatments, making systemic treatment, with all its
side-effects, inevitable. Therefore, there is a need for the
development of new local treatments for patients with
distal colitis or proctitis.
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Tacrolimus, formally known as FK506, is one of the
calcineurin inhibitors found to be effective for the systemic
treatment of ulcerative colitis [2–6]. We [7] and others [8]
recently described the therapeutic effect of local tacrolimus
treatment in patients with therapy-resistant distal colitis in
two pilot studies.
The aim of this study was to validate local application of
tacrolimus in IBD by studying the immunomodulatory
effect of this drug on several classes of immune cells that
are implicated in the aberrant mucosal immune responses
associated with IBD, e.g., epithelial cells, antigen pre-
senting cells, and lamina propria T cells. A subset of T
cells, namely the CD1d-restricted NKT cells, have also
been implicated in IBD pathogenesis [9]. Therefore, we
also studied the effect of tacrolimus on this specific subset
of T cells. Furthermore we assessed the levels of tacrolimus
within colonic tissue and the extent of local immune sup-
pression after rectal administration in mice.
Methods
In Vitro Studies
Treatment of Epithelial Cells with Tacrolimus
A colonic epithelial cell line (Caco-2) was pre-incubated
for 6 h with a range of tacrolimus (Prograf, Fujisawa)
concentrations, from 0 to 100,000 ng/ml, washed three
times, and subsequently stimulated with 30 lg/ml pepti-
doglycan (from bacillus subtilis, Fluka/Sigma-Aldrich).
After 24 h of incubation with tacrolimus, IL-8 production
was measured in the supernatant by means of enzyme-
linked immunosorbent assay (ELISA, OptEIA mouse IL-8
ELISA set, BD Biosciences Pharmingen).
Treatment of (NK)-T Cells with Tacrolimus
Colonic lamina propria mononuclear cells were isolated
from naı¨ve BALB/C mice as described earlier [10] and
were stimulated ex vivo with 2 lg/ml aCD3 (BD Biosci-
ences, clone 145-2C11) and 2 lg/ml aCD28 (BD Biosci-
ences, clone 37.51) antibodies in the presence of a range of
tacrolimus concentrations. After 72 h supernatant was
collected and IL-2 concentrations were measured by means
of ELISA (OptEIA, human IL-2 ELISA set, BD Biosci-
ences Pharmingen).
A CD1d-restricted NKT cell line (DN32.D3), kindly
provided by Richard Blumberg, was pre-treated with a
range of tacrolimus concentrations, from 0 to 1,000 ng/ml,
for 24 h. Subsequently, NKT cells were stimulated with
5 ng/ml phorbol ester 12-tetradecanoylphorbol-13 acetate
(PMA, Sigma-Aldrich) and 100 ng/ml calcium ionofore
(Sigma-Aldrich). After 24 h of stimulation, IL-2 concen-
trations were measured in the supernatant by means of
ELISA.
Treatment of Antigen Presenting Cells with Tacrolimus
Dendritic cells were cultured from BALB/C bone marrow as
previously described [11]. Thereafter, the protein ovalbumin
(OVA) (calbiochem, EMD biosciences) was added at a
concentration of 1 mg/ml and incubated in the presence of a
range of tacrolimus concentrations. After 6 h, the DCs were
Fig. 1 Tacrolimus inhibits the activity of mucosal T cells and antigen-
presenting cells but leaves epithelial cells unaffected in vitro. Aster-
isks indicate statistical significance (P \ 0.05), bars represent the
mean of at least four wells per condition. Error bars indicate the
standard error of the mean. The data shown are representative for at
least two independent experiments. a Caco-2 cells were pre-incubated
for 6 h with increasing amounts of tacrolimus and subsequently
stimulated with peptidoglycan for 24 h. Bars indicate the average IL-8
production. The grey bar indicates the basal release of IL-8 of
unstimulated Caco-2 cells. White bars indicate IL-8 production of
peptidoglycan stimulated Caco-2 cells, incubated with increasing
amounts of tacrolimus. Tacrolimus did not result in a significant
inhibition of IL-8 production by epithelial cells. b Lamina propria
lymphocytes (LPL) were isolated from murine colon and stimulated
ex vivo for 72 h with aCD3/aCD28 antibodies in the presence of
increasing amounts of tacrolimus. IL-2 was measured in the super-
natant by means of ELISA. Bars indicate the average IL-2 production.
Significant inhibition of IL-2 production was observed at a tacrolimus
dose of 1 ng/ml. c NKT cells derived from the cell line DN32.D3 were
pre-treated for 24 h with a range of tacrolimus concentrations and
subsequently stimulated with PMA/calcium-ionophore for another
24 h. IL-2 was measured in the supernatant by means of ELISA. Bars
indicate the average IL-2 production of NKT cells. A dose-dependent
inhibition of IL-2 production by tacrolimus is observed. d–f Dendritic
cells were loaded with the protein antigen OVA in the presence of
increasing amounts of tacrolimus and washed three times after 6 h of
incubation. Subsequently, DCs were co-cultured for 72 h with CFSE-
labeled T cells, which have a transgenic OVA-specific T cell receptor
(DO11-10 T cells). d Proliferation of T cells was analyzed by FACS
analysis of CFSE-positive cells. CD4 positivity is shown on the
Y-axis. CFSE positivity is shown on the X-axis. As CFSE is equally
divided over daughter cells in a cell division, decreasing levels of
CFSE indicate the number of divisions the cells have undergone. A
high number of cells remain in an undivided state when DCs were
incubated with tacrolimus. e Percentages shown in this graph are
derived from the FACS data shown above (Fig. 1d). Bars indicate the
percentage of cells within a specific round of division. Tacrolimus
inhibits the capacity of DCs to induce division of T cells as there is a
shift towards a higher percentage of undivided T cells and T cells that
are in their first division and a lower percentage of cells that are in their
third or fourth divisions. f IFN-c production was measured in the
supernatant after 72 h by means of ELISA. Bars indicate the average
IFN-c production of T cells. A dose-dependent decrease of IFN-c
production is observed. g The Cd1d transfected epithelial cell line
T84d was loaded with the lipid antigen aGalCer in the presence of
increasing amounts of tacrolimus and washed three times after 18 h of
incubation. Subsequently, T84d cells were co-cultured for 24 h with
DN32.D3 cells, which have a aGalCer responsive T cell-receptor. IL-2
was measured in the supernatant by means of ELISA. Bars indicate the
average IL-2 production by DN32.D3 cells. A dose-dependent
decrease of IL-2 production is observed
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harvested, washed three times with medium, and the viable
DCs were counted and plated in a 96-well culture plate.
Meanwhile, T cells with an OVA specific T cell receptor
were isolated from DO-11-10 mice and labeled with 5 lM
CFSE (Molecular Probes). DCs and T cells were co-cultured
at a ratio of 1:10 and harvested after 72 h. Proliferation of
lymphocytes was determined by flow cytometric analysis
(FACStar, BD Biosciences). Thereto, cells were stained
with CD4 and Kj (which is the marker for the OVA specific
T cell receptor) antibodies (CD4-PE, clone L3T4- GK1.5,
BD Biosciences Pharmingen and KJ1-26 anti-TCR-biotin,
Caltag, Burlingame, CA, respectively). After FACS mea-
surement, CFSE peaks were analyzed within a CD4/Kj
double positive gate. Culture supernatants were analyzed
after 72 h for IFN-c production by means of ELISA (using
anti-mouse INF-c, clone XMG 1.2, Biolegend).
The epithelial cell line T84d, kindly provided by Richard
Blumberg, which is an epithelial cell line transfected with
the non-classical antigen-presenting molecule CD1d
[12, 13], was loaded with 100 ng/ml of the NKT cell-
specific lipid antigen a-galactosylceramide (aGalCer,
Alexis Biochemicals) in the presence of a range of tacrol-
imus concentrations. After 18 h of incubation, the epithelial
cells were washed three times with medium and subse-
quently co-cultured at a ratio of 1:1 with NKT cells (of the
cell line DN32.D3), which have a aGalCer responsive T cell
receptor. After 24 h, the supernatant was collected and IL-2
production was determined by means of ELISA.
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In Vivo Studies: Mice
All animal procedures and protocols were performed with
the approval of the local institutional animal studies ethics
committee. All mice were purchased from Charles-River.
At least four animals per treatment group were used.
Tacrolimus Enema Treatment of Naı¨ve Mice
The first experiment was to compare colonic and blood
levels of tacrolimus upon oral or intra-rectal tacrolimus
treatment. Eight- to ten-week-old BALB/C mice were
anaesthetized with isoflurane-gas and 150 ll of tacrolimus
0.1 mg/ml was installed either locally in the colon by
means of a catheter or intra-gastrically by means of a oro-
gastric gavage. The mice were killed 18 h after drug
administration. Blood was collected in EDTA (1.5 mg/ml)
and the colon was divided into a proximal part and a distal
part. Tissue was homogenized in a buffer containing
20 mM Tris (pH 7.4), 10 lg/ml leupeptin (Sigma-Aldrich),
200 mU/ml aprotinin (Sigma-Aldrich), and 20 lg/ml phe-
nyl methyl sulphonyl fluoride [14] using a Polytron
homogenizer (PT1200, Kinematica AG, Switzerland).
Protein levels were then determined in colonic homoge-
nates using the Pierce Bicinchoninic acid assay (BCA,
Interchim). Subsequently, tacrolimus levels were deter-
mined in 1 mg colonic protein and in blood using a ta-
crolimus ELISA (PRO-Trac II, Diasorin).
A second experiment was setup to determine whether
immune suppression was achieved at 18 h of local
administration of tacrolimus. Eight- to ten-week-old
BALB/C mice were anaesthetized by isoflurane-gas and
150 ll of tacrolimus 0 or 1 mg/ml was installed in the
colon. The mice were killed after 18 h and lamina propria
lymphocytes—(LPL), iliac lymph node—(ILN), mesen-
teric lymph node—(MLN) and spleen-lymphocytes were
isolated and subsequently cultured and stimulated with
2 lg/ml aCD3 and 2 lg/ml aCD28 antibodies as described
previously [10]. After 72 h, the supernatant was collected
and IL-2 concentration was measured by means of ELISA.
Results
Tacrolimus Inhibits Activity of Local T Cells and
Antigen-Presenting Cells but Leaves Epithelial Cells
Unaffected In Vitro
To study whether tacrolimus is able to directly affect cells
that are present in the colonic mucosa, the immunomodu-
latory effects were studied in vitro on several cell lines and
ex vivo isolated cells.
First, the immunomodulatory effect of tacrolimus on
colonic epithelial cells was evaluated. Caco-2 cells that
were pretreated with tacrolimus before stimulation with
peptidoglycan did not show an inhibition of their capacity
to produce the chemokine IL-8 (Fig. 1a). Importantly,
tacrolimus did not cause an increase of epithelial cell death at
any of the used tacrolimus concentrations (data not shown).
Second, the effect of tacrolimus on local subsets of T
cells was evaluated. First, we aimed to determine whether
local lymphocytes were susceptible to immunomodulatory
effects of tacrolimus in vitro. LPLs isolated from murine
colon and stimulated with aCD3 and aCD28 antibodies
ex vivo in the presence of tacrolimus display a total
blockade of their IL-2 production at a dose of 10 ng/ml
tacrolimus (Fig. 1b). The activation of an NKT cell line
stimulated by a phorbol ester was inhibited by tacrolimus
in a dose-dependent manner (Fig. 1c).
Third, the effect of tacrolimus on antigen presentation
was evaluated as this process is crucially implicated in
colonic inflammation. Thereto, DCs were loaded with the
protein antigen OVA in the presence or absence of ta-
crolimus prior to consecutive incubation with T cells that
have an OVA-specific T cell receptor (DO11-10 T cells).
DCs treated with tacrolimus were less able to stimulate T
cells to proliferate and produce IFN-c. After 72 h of co-
incubation with tacrolimus, pre-treated DCs T cells showed
a dose-dependent increase in the percentage of undivided
cells (Fig. 1d, e) and a dose-dependent decrease of their
IFN-c production (Fig. 1f). This inhibitory effect of
tacrolimus on antigen presentation did not seem to be
restricted to classical protein antigen presentation since the
same results were obtained when this experiment was
performed in a system that is independent of classical
MHC (-II) presentation but dependent of a lipid non-clas-
sical Cd1d-restricted pathway (Fig. 1g).
Colonic Application of Tacrolimus Results in Local
Retention and Local Immune Suppression
We compared colonic and systemic tacrolimus levels after
oral administration, which is the common route for systemic
therapy, and after intra-rectal administration. As demon-
strated by Fig. 2a, blood levels of intra-rectal treated mice
are similar to blood levels of orally treated mice after 18 h of
treatment. Importantly, upon rectal administration, a 14-fold
higher concentration of tacrolimus was reached within
colonic tissue in comparison to oral administration (Fig. 2a).
To study immunomodulatory effects after local treat-
ment with tacrolimus ILN-, LPL-, MLN- and spleen lym-
phocytes were isolated from rectal tacrolimus-treated mice
after 18 h. These cells were stimulated polyclonally
ex vivo with aCD3 and aCD28 antibodies. After 48 h of
stimulation, IL-2 concentration was measured in the
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supernatant. Lymphocytes derived from colon draining
ILNs of tacrolimus-treated mice show a significant inhi-
bition of IL-2 production compared to lymphocytes of the
saline-treated mice. Lymphocytes derived from the lamina
propria of mice treated with tacrolimus also displayed less
IL-2 production than lamina propria T cells from mice
treated with saline only, albeit not significantly. Local
tacrolimus treatment did not affect the IL-2 production of
spleen or MLN-derived lymphocytes (Fig. 2b).
Discussion
In these studies we sought substantiation of tacrolimus as a
local therapeutic in IBD patients. First we established that
tacrolimus elicits a potent immunosuppressive effect on
several mucosal immune cells that are crucially implicated in
the pathogenesis of IBD. As such, our in vitro experiments
show that IL-2 production of both lamina propria T cells as
well as an NKT cell line was strongly inhibited by tacrolimus
in a dose-dependent fashion. Notably, recent work has
implicated that NKT cells play an important role in the IBD
pathogenesis and these cells may therefore serve as a new
target for immunomodulatory therapy in IBD. The suppres-
sion of IL-2 is a well-known feature of calcineurin inhibitors.
Also, systemic tacrolimus administration has been linked to
mucosal immune suppression in previous work [15], how-
ever, the direct effect on the normally resilient mucosal T
cells and NKT cells had not been studied earlier.
Interestingly, we observed that the activation of T cells
or NKT cells could also be inhibited indirectly by targeting
antigen-presenting cells with tacrolimus. Both MHC class
II restricted and non-restricted antigen presentation was
strongly inhibited by tacrolimus. It has been suggested
earlier that tacrolimus inhibits the T cell stimulatory
capacity of DCs [16–18]. Here we show that this concept
can be extended to non-classical ways of lipid antigen
presentation. The mechanism behind these observations
has yet to be clarified but may also involve calcineurin-
dependent processes. Calcineurin inhibitors specifically
affect lymphocytes as their activation critically depends on
a restricted amount of the phosphatase. At higher (local)
concentrations of tacrolimus the activity of the drug may be
less restricted to lymphocytes and also affect cells that are
less dependent on calcineurin [19, 20]. Importantly, we did
not observe any suppressive effects of tacrolimus on the
responsiveness of epithelial cells to bacterial peptidogly-
can. The latter suggests that one of the hallmarks of
mucosal homeostasis that is microbial sensing by the epi-
thelium will remain intact during tacrolimus treatment.
Fig. 2 Colonic application of tacrolimus in mice results in mainly
local presence of the drug and local immune suppression. a Mice were
treated with 150 ll of tacrolimus (0.1 mg/ml) either intrarectally or
intragastrically. Eighteen hours later, mice were sacrificed and colons
and blood were removed. Colons were divided into a proximal part and
a distal part, and homogenized. Tacrolimus levels were measured in
blood and the homogenates by means of ELISA. The first four bars
reflect the concentration of tacrolimus present in the colon (ng per mg
protein). The last two bars represent the concentration of tacrolimus
present in the blood (ng per ml). Irrespective of the route of
administration, at 18 h after tacrolimus treatment, comparable amounts
of tacrolimus are detectable in the blood. Tacrolimus was present in the
colon in higher amounts after rectal than after oral administration of the
drug. b Mice were treated with 150 ll of tacrolimus (1 mg/ml) or saline
intrarectally. At 18 h after treatment, lymphocytes were isolated from
lamina propria, iliac lymph node, mesenteric lymph node, and spleen,
and stimulated for 72 h with aCD3aCD28 antibodies. IL-2 production
was measured in the supernatant by means of ELISA. Bars represent the
average IL-2 production of at least four mice. Lamina propria-derived
lymphocytes (LPL) and colon draining lymph node-derived lympho-
cytes (ILN) of tacrolimus-treated mice tend to produce less IL-2 upon
polyclonal stimulation than lymphocytes derived from saline-treated
mice, whereas no differences in IL-2 production were observed within
systemically derived lymphocytes. Asterisks indicate statistical signif-
icance (P \ 0.05). Error bars indicate the standard error of the mean
c
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A next step in our studies was to prove that locally
applied tacrolimus is retained in the mucosa and elicits its
immune suppression only at the local site of application.
We found that rectal application of tacrolimus yielded
much higher mucosal levels of this drug compared to oral
treatment whereas systemic levels were quite similar with
both administration routes. This implicates that much lower
doses of tacrolimus are required to obtain a therapeutic
level in the colon after local application than after systemic
application, which limits systemic tacrolimus levels. This
experiment illustrates that there is a difference in mucosal
levels, depending on the route of administration. As there
are pharmacokinetic differences between mice and
humans, we decided not to extend in this current protocol.
For further insight into (mucosal) tacrolimus pharmacoki-
netics, human studies should be performed.
As anticipated, mice treated with tacrolimus rectally dis-
played inhibited immune responses of cells derived from the
local draining lymph nodes, whereas more distal (mesenteric
lymph nodes) and concurrent systemic (spleen) immune
responses remained intact. These data confirm that tacrolimus
is indeed retained and active in the mucosa at the local site of
application. A proper dose-finding study in humans should
reveal which dosage is best suited for use in patients.
These studies show that tacrolimus has potent immune-
suppressive capacities when applied directly upon the
mucosa. In vitro, it potently inhibits activation of lamina
propria (NK)T cells and of both classical as well as non-
classical antigen presentation, while leaving epithelial
microbial defense intact. In vivo application of tacrolimus
in murine colons yielded an inhibited local T cell response
ex vivo, while leaving systemic T cell responses intact.
High colonic levels of tacrolimus were reached after rectal
administration in comparison to systemic (oral) treatment
in mice. This implicates that lower doses of tacrolimus may
be used in local application, limiting systemic side-effects.
These data provide a rationale to further study local
application of tacrolimus in IBD patients.
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